Leerink raises price targets on Axogen and Replimune, keeps Outperform ratings
Leerink Partners kept Outperform ratings on Axogen and Replimune and raised price targets, with Axogen moving to $56 and Replimune to $31 from prior levels.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Leerink Partners kept its Outperform rating on Axogen and lifted its price target to $56 from $52, an increase of 7.7%. The new target points to 13.7% upside from the October 28 close of $49.25, according to TradingView. Across the five latest analyst notes over the past 30 days, targets range from $52 to $60.
For Replimune Group, Leerink also kept Outperform and raised its target to $31 from $19, a 63.2% jump. That target implies 93.0% upside from the October 28 close of $16.06. Benzinga supplies the reference data, as reported by TradingView.
why it matters
Routine target revisions like these are common and rarely move the broader market. For small-cap names, a higher target mainly reflects one analyst's view and does not guarantee where the shares will trade.
tags
instruments
sources
- Leerink Partners maintains Axogen at Outperform, raises price target to $56 from $52 — TradingView, 29 October 2026 at 18:50 UTC
- Leerink Partners maintains Replimune Group at Outperform, raises price target to $31 from $19 — TradingView, 29 October 2026 at 18:59 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗